Jul. 30 at 3:59 PM
$ELTP $GME $PFE $BTC.X
The Number don't Lie. ELTP is Hot. Rumors are based on Facts.
Elite Pharmaceuticals reported third-quarter fiscal 2026 results for the three months ended December 31, 2025. Revenue was
$31.6 million, up about 120% year-over-year. Income from operations was
$9.0 million, up 721%. Net income was
$18.6 million.
The company attributed the profit increase primarily to sales of newly launched lisdexamfetamine and naltrexone products plus strong growth in Elite-label lines.